Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Bethel MA, Stevens SR, Buse JB, Choi J, et al. Circulation 2020;141:1360-1370.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bethel MA, Stevens SR, Buse JB, Choi J, et al. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation 2020;141:1360-1370.
PMID: 32098501